Articles tagged "Highly-sensitized"

2019 American Transplant Congress
5-Year Post-Transplant Outcomes with Bortezomib-Based Desensitization in Renal Transplant Recipients
K. Zheng¹, S. Tremblay¹, A. R. Shields², M. A. Cardi², J. Kremer², R. R. Alloway¹, E. S. Woodle¹
¹U of Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: Renal transplant (RT) after desensitization (DS) has been associated with increased rejection rates. Proteasome inhibitor(PI)-based DS yields significant reductions in HLA Ab among sensitized…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…
2019 American Transplant Congress
Outcomes in Preformed Donor-Specific Human Leukocyte Antibody Positive Living Kidney Transplant Recipients Desensitized with Intravenous Immunoglobulin and Rituximab
Y. kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and is a significant immunologic barrier to graft and patient survival. Pre-transplant desensitization therapy has…
2019 American Transplant Congress
Safety and Efficacy of Imlifidase in Highly-Sensitized Kidney Transplant Patients: Results from a Phase 2 Study
S. C. Jordan¹, C. Legendre², N. Desai³, T. Lorant⁴, M. Bengtsson⁴, L. Laxmyr⁵, B. Lonze⁶, A. Vo¹, K. J. Wood⁷, C. Kjellman⁵, R. A. Montgomery⁶
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Hopital Necker, Paris, France, ³Johns Hopkins University, Baltimore, MD, ⁴Uppsala University, Uppsala, Sweden, ⁵Hansa Medical AB, Lund, Sweden, ⁶NYU Langone Health Transplant Institute, New York, NY, ⁷University of Oxford, Oxford, United Kingdom
*Purpose: Many patients eligible for kidney transplantation are sensitized to allo-HLA antigens and face prolonged waiting times and increased mortality. The presence of donor specific…
2019 American Transplant Congress
Hepatitis Flare in Hepatitis B Core Antibody Positive Kidney Recipients Treated with Rituximab
M. Raja¹, Y. Natori¹, C. Donato¹, D. De Lima¹, J. Rivollo², A. Centeno², Y. Ebisu¹, L. Abbo¹, J. Simkins¹, S. Anjan¹, J. Camargo¹, M. I. Morris¹
¹Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, ²Jackson Memorial Hospital, Miami, FL
*Purpose: Patients with Hepatitis B Core Antibody (anti-HBc Ab) positive are known to be at risk for Hepatitis B virus (HBV) reactivation during periods of…
2019 American Transplant Congress
Anti-HLA IgM Antibodies Are Reduced in Highly-HLA Sensitized Patients Transplanted after Imlifidase (IdeS) Treatment
X. Zhang¹, S. Jordan²
¹HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA
*Purpose: Immunoglobulin-degrading enzyme from Streptococcus pyogenes (IdeS, Imlifidase) has been used to reduce antibody levels to promote transplant of highly sensitized patients. In vitro experiments…
2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
A. Casillas-Abundis, A. Tambur, A. Shetty, C. D'Agostino, J. R. Leventhal
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…
2019 American Transplant Congress
Bortezomib Based Induction Therapy Decreases Delayed Graft Function in High Risk Kidney Transplantation
K. Mahendran¹, N. Koizumi², J. K. Melancon¹
¹Transplant Institute, The George Washington University, Washington, DC, ²Schar School of Policy and Government, George Mason University, Arlington, VA
*Purpose: Over 100,000 candidates await a kidney transplant on the national United Network for Organ Sharing (UNOS) waitlist. Among these candidates, one-third have pre-formed antibodies…
2019 American Transplant Congress
Overcoming Anti-HLA Sensitization in Kidney Transplantation
R. C. Siqueira¹, P. Malafronte², J. C. Baptista-Silva², E. F. Silva², M. C. Camargo², M. C. Ribeiro Castro²
¹Nephrology Post-Graduation, University of Sao Paulo, São Paulo, Brazil, ²Kidney Transplant Unit, Hospital Samaritano de São Paulo, São Paulo, Brazil
*Purpose: To evaluate if it is possible to achieve good results in kidney transplantation (Ktx) regardless the degree of anti-HLA sensitization.*Methods: 143 adult living (LD)…
2018 American Transplant Congress
A Follow-Up Report on the Use of IVIG+Rituximab to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly-Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
R. Najjar, E. Huang, A. Vo, J. Choi, K. Lim, S. Louie, A. Peng, S. Sethi, M. Toyoda, X. Zhang, S. Jordan.
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) with IVIG/rituximab is associated with a reduction in donor specific antibodies (DSA), improved transplant rates and outcomes in highly-sensitized (HS) patients. We…

« Previous Page
1
…
5
6
7
8
9
…
15
Next Page »